growing - deloitte what's...disruption opportunities patients disruption opportunity ecosystem...
TRANSCRIPT
Precise Bio is whereregenerative medicine
Growing a completelive & vitalcomplicated organ
meets 3D printing
Anthony Atala MDCo Founder & CMO
W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine. He is recognized as a worldwide leader in regenerative medicine and its clinical translation. Dr. Atala is a member of the Institute of Medicine of the National Academy of Sciences, and serves as President of the Regenerative Medicine Foundation.
Aryeh BattCo Founder & CEO
Over 25 years of experience in leading product management and development of cutting edge technology products from research stages to marketing & sales. Aryeh was VP Business and Director of Corporate R&D at Orbotech (Nasdaq: ORBK). Aryeh was VP R&D and then VP BD & CTO at MangoDSP(signal processing). He holds a BSc in Physics and Electro optics engineering from JCT.
Shay Soker PhDCo Founder & CSO
Professor of Regenerative Medicine and Biomedical Engineering at the Wake Forest School of Medicine. Expert in molecular and cellular biology, and natural biomaterials, with more than 18 years experience in tissue and organ engineering. Some of Dr. Soker’s projects have moved to clinical translation while others are being discussed with industry.
Ran MatokiCFO
Over 20 years of Executive Financial roles in North America, Europe and Israel. Ran’s experience includes -$500M in exits, $6.7B in M&As, and $550M in equity funding – from startups to Enterprises. Ran was the CFO of Better Place Israel and prior to that the CFO & COO of Global SAP Partners and Ecosystem division. He is CPA, and Executive MBA (Major in Finance).
Can we grow complicated organsinstead of harvesting them?
Regenerative Medicine meets
3D printing
Engineered Blood Vessel
Cell Technology
Progenitor cells and specific growth factors: expansion potential
1cm2
Day 1 ( 5 x 104 cells)
Day 60 ( 50 x 109 cells)Enough cells to cover a football field
Market Disruption
Market Disruption
Market Disruption
Organ injury due to motor vehicle accident
Pre repair Post repair
First Engineered Organ in Humans: Bladder
Regenerative medicine current challenge
Technology Uniqueness
Ink jet Extrusion Laser Assisted
Resolution 50µm 100µm 1µm
Viscosity Up to 10mPa/s 106mPa/s 106mPa/s
Cell vitality <85% 40-80% >95%
Source: Nature Biotechnology August 2014 Volume 32
Printing of human liver SINGLE cells
The Precise Process
1Sourcing
2Expansion
3 4Deposition
5Maturing
Manual Structuring
Simple Organ
3D Printing
Semi Complex
Organ
Complex Organ
Preparing
Facing Regulation
Expertise Clinical trial Facility
Market Disruption
Cost effective Quality Time
Disruption OpportunitiesPatients
Disruption
Opportunity
ReimbursementsOperationsEcosystem
Affordable, qualitative and time related transplants
Lowering transplants risks and cost
Significantly increasing transplants volume
Curing disease and preventing illness - WW
HMOs, Health InsuranceSurgeons & operations Drs.
Cells expansion, Bio ink, stems cells, Organ imaging
Blue Ocean and higher ‘production possibility frontier’
From saving lives
125Kpeople on the
waiting list in the US
From saving lives
$6Bin the US in Life
saving procedures
To improve quality of life
$100BWorldwide in
all procedures
First Organ – Cardiac Patch
Unmet need | Functional Semi-complex | A-Z manual ‘know how’
• 50% / 5 yrs after MI - Heart Failure
• Remodeling • Cardiac Patch reduces risk and
retrieves functionality
Engineered Heart Valve
Precise Bio is whereregenerative medicine
Growing a completelive & vitalcomplicated organ
meets 3D printing
Thank you
Engineered tissue
BladderBlood vesselBoneCartilageCorneaCorporaDiaphgramEarFasciaFat
HeartHeart valveIntestineKidneyLiverNasal TurbinateNerveOvaryPancreasSalivary glands
Skeletal MuscleSkinSmooth MuscleTendonTestisTracheaUrethraUrinary SphincterUterusVagina